Lupin Partners With SteinCares To Supply Biosimilar in LATAM
ECONOMY & POLICY

Lupin Partners With SteinCares To Supply Biosimilar in LATAM

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.

As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.

Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).

Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”

Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”

This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code